Stifel Initiates Coverage On NewAmsterdam Pharma Co with Buy Rating, Announces Price Target of $44

Benzinga · 06/10 14:25
Stifel analyst James Condulis initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announces Price Target of $44.